Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy

A switch study

Xiaohong Wang, Robert Savage, Andrey Borisov, Jill Rosenberg, Bobbi Woolwine, Melanie Tucker, Roberta May, Jacqueline Feldman, Charles Nemeroff, Andrew H. Miller

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The objective of the study was to examine whether patients with schizophrenia who were judged to be stable on long-term treatment with conventional antipsychotic medications would further benefit from a switch to an atypical antipsychotic drug. Thirty-six subjects with schizophrenia spectrum disorder, on conventional antipsychotic medication therapy for at least 2 years, were randomized in double-blind fashion to risperidone versus olanzapine. Patients were titrated up to 6 mg risperidone or 15 mg olanzapine as tolerated, followed by tapering and discontinuation of conventional antipsychotic medication. Atypical antipsychotic agents were then administered alone (monotherapy) for 12 weeks. Efficacy and tolerability were assessed using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale, and Simpson Angus Scale. Body weight was measured at each visit. Both treatment groups exhibited marked and similar improvement in the total PANSS score from baseline to study endpoint (22 weeks) [risperidone: baseline = 59.3 (SE 3.1), 22 weeks = 44.3 (SE 2.3) (p < 0.001); olanzapine: baseline = 55.9 (SE 3.3), 22 weeks = 46.9 (SE 3.2) (p < 0.001). Both groups also exhibited significant reductions in PANSS factor scores for positive and negative symptoms and disorganized thoughts. Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression. Of note, while positive factor scores exhibited the majority of change within the first 10 weeks, negative factor scores continued to decline significantly in both treatment groups throughout the study. Tolerability assessments did not differ between groups. The results indicate that both atypical antipsychotic medications provided significant additional improvement in symptom severity in patients with schizophrenia previously on conventional antipsychotic agents.

Original languageEnglish
Pages (from-to)669-676
Number of pages8
JournalJournal of Psychiatric Research
Volume40
Issue number7
DOIs
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

olanzapine
Risperidone
Antipsychotic Agents
Schizophrenia
Therapeutics
Hostility
Anxiety
Body Weight

Keywords

  • Atypical antipsychotic medication
  • Olanzapine
  • Psychopharmacology
  • Randomized clinical trial
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy : A switch study. / Wang, Xiaohong; Savage, Robert; Borisov, Andrey; Rosenberg, Jill; Woolwine, Bobbi; Tucker, Melanie; May, Roberta; Feldman, Jacqueline; Nemeroff, Charles; Miller, Andrew H.

In: Journal of Psychiatric Research, Vol. 40, No. 7, 01.10.2006, p. 669-676.

Research output: Contribution to journalArticle

Wang, Xiaohong ; Savage, Robert ; Borisov, Andrey ; Rosenberg, Jill ; Woolwine, Bobbi ; Tucker, Melanie ; May, Roberta ; Feldman, Jacqueline ; Nemeroff, Charles ; Miller, Andrew H. / Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy : A switch study. In: Journal of Psychiatric Research. 2006 ; Vol. 40, No. 7. pp. 669-676.
@article{b09449dde806405e9d68d7254993c117,
title = "Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study",
abstract = "The objective of the study was to examine whether patients with schizophrenia who were judged to be stable on long-term treatment with conventional antipsychotic medications would further benefit from a switch to an atypical antipsychotic drug. Thirty-six subjects with schizophrenia spectrum disorder, on conventional antipsychotic medication therapy for at least 2 years, were randomized in double-blind fashion to risperidone versus olanzapine. Patients were titrated up to 6 mg risperidone or 15 mg olanzapine as tolerated, followed by tapering and discontinuation of conventional antipsychotic medication. Atypical antipsychotic agents were then administered alone (monotherapy) for 12 weeks. Efficacy and tolerability were assessed using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale, and Simpson Angus Scale. Body weight was measured at each visit. Both treatment groups exhibited marked and similar improvement in the total PANSS score from baseline to study endpoint (22 weeks) [risperidone: baseline = 59.3 (SE 3.1), 22 weeks = 44.3 (SE 2.3) (p < 0.001); olanzapine: baseline = 55.9 (SE 3.3), 22 weeks = 46.9 (SE 3.2) (p < 0.001). Both groups also exhibited significant reductions in PANSS factor scores for positive and negative symptoms and disorganized thoughts. Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression. Of note, while positive factor scores exhibited the majority of change within the first 10 weeks, negative factor scores continued to decline significantly in both treatment groups throughout the study. Tolerability assessments did not differ between groups. The results indicate that both atypical antipsychotic medications provided significant additional improvement in symptom severity in patients with schizophrenia previously on conventional antipsychotic agents.",
keywords = "Atypical antipsychotic medication, Olanzapine, Psychopharmacology, Randomized clinical trial, Risperidone, Schizophrenia",
author = "Xiaohong Wang and Robert Savage and Andrey Borisov and Jill Rosenberg and Bobbi Woolwine and Melanie Tucker and Roberta May and Jacqueline Feldman and Charles Nemeroff and Miller, {Andrew H.}",
year = "2006",
month = "10",
day = "1",
doi = "10.1016/j.jpsychires.2006.03.008",
language = "English",
volume = "40",
pages = "669--676",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy

T2 - A switch study

AU - Wang, Xiaohong

AU - Savage, Robert

AU - Borisov, Andrey

AU - Rosenberg, Jill

AU - Woolwine, Bobbi

AU - Tucker, Melanie

AU - May, Roberta

AU - Feldman, Jacqueline

AU - Nemeroff, Charles

AU - Miller, Andrew H.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - The objective of the study was to examine whether patients with schizophrenia who were judged to be stable on long-term treatment with conventional antipsychotic medications would further benefit from a switch to an atypical antipsychotic drug. Thirty-six subjects with schizophrenia spectrum disorder, on conventional antipsychotic medication therapy for at least 2 years, were randomized in double-blind fashion to risperidone versus olanzapine. Patients were titrated up to 6 mg risperidone or 15 mg olanzapine as tolerated, followed by tapering and discontinuation of conventional antipsychotic medication. Atypical antipsychotic agents were then administered alone (monotherapy) for 12 weeks. Efficacy and tolerability were assessed using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale, and Simpson Angus Scale. Body weight was measured at each visit. Both treatment groups exhibited marked and similar improvement in the total PANSS score from baseline to study endpoint (22 weeks) [risperidone: baseline = 59.3 (SE 3.1), 22 weeks = 44.3 (SE 2.3) (p < 0.001); olanzapine: baseline = 55.9 (SE 3.3), 22 weeks = 46.9 (SE 3.2) (p < 0.001). Both groups also exhibited significant reductions in PANSS factor scores for positive and negative symptoms and disorganized thoughts. Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression. Of note, while positive factor scores exhibited the majority of change within the first 10 weeks, negative factor scores continued to decline significantly in both treatment groups throughout the study. Tolerability assessments did not differ between groups. The results indicate that both atypical antipsychotic medications provided significant additional improvement in symptom severity in patients with schizophrenia previously on conventional antipsychotic agents.

AB - The objective of the study was to examine whether patients with schizophrenia who were judged to be stable on long-term treatment with conventional antipsychotic medications would further benefit from a switch to an atypical antipsychotic drug. Thirty-six subjects with schizophrenia spectrum disorder, on conventional antipsychotic medication therapy for at least 2 years, were randomized in double-blind fashion to risperidone versus olanzapine. Patients were titrated up to 6 mg risperidone or 15 mg olanzapine as tolerated, followed by tapering and discontinuation of conventional antipsychotic medication. Atypical antipsychotic agents were then administered alone (monotherapy) for 12 weeks. Efficacy and tolerability were assessed using the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale, and Simpson Angus Scale. Body weight was measured at each visit. Both treatment groups exhibited marked and similar improvement in the total PANSS score from baseline to study endpoint (22 weeks) [risperidone: baseline = 59.3 (SE 3.1), 22 weeks = 44.3 (SE 2.3) (p < 0.001); olanzapine: baseline = 55.9 (SE 3.3), 22 weeks = 46.9 (SE 3.2) (p < 0.001). Both groups also exhibited significant reductions in PANSS factor scores for positive and negative symptoms and disorganized thoughts. Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression. Of note, while positive factor scores exhibited the majority of change within the first 10 weeks, negative factor scores continued to decline significantly in both treatment groups throughout the study. Tolerability assessments did not differ between groups. The results indicate that both atypical antipsychotic medications provided significant additional improvement in symptom severity in patients with schizophrenia previously on conventional antipsychotic agents.

KW - Atypical antipsychotic medication

KW - Olanzapine

KW - Psychopharmacology

KW - Randomized clinical trial

KW - Risperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=33748300680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748300680&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2006.03.008

DO - 10.1016/j.jpsychires.2006.03.008

M3 - Article

VL - 40

SP - 669

EP - 676

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 7

ER -